Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
Xu, Chen
Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type. [electronic resource] - Oncotarget May 2017 - 33185-33196 p. digital
Publication Type: Journal Article
1949-2553
10.18632/oncotarget.16567 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological--administration & dosage
Biomarkers, Tumor
Female
Humans
Immunohistochemistry
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Receptor, ErbB-2--metabolism
Stomach Neoplasms--drug therapy
Survival Analysis
Trastuzumab--administration & dosage
Treatment Failure
Treatment Outcome
Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type. [electronic resource] - Oncotarget May 2017 - 33185-33196 p. digital
Publication Type: Journal Article
1949-2553
10.18632/oncotarget.16567 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological--administration & dosage
Biomarkers, Tumor
Female
Humans
Immunohistochemistry
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Receptor, ErbB-2--metabolism
Stomach Neoplasms--drug therapy
Survival Analysis
Trastuzumab--administration & dosage
Treatment Failure
Treatment Outcome